CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 67,500 shares of its common stock to one new employee, consisting of stock options to purchase 45,000 shares of common stock and restricted stock units (“RSUs”) covering 22,500 shares of
Business Wire Stock Sale/Buyback News